PriceTargets.com logo

Celularity - CELU Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.03 As of 04/19/2024 01:00 AM ET
▼ -0.18 (-5.61%)

This chart shows the closing price for CELU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celularity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CELU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CELU

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Celularity in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.03.

This chart shows the closing price for CELU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Celularity. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/30/2023HC WainwrightLower TargetBuy$150.00 ➝ $25.00Low
1/30/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$50.00 ➝ $10.00Low
12/22/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
9/12/2022Morgan StanleyLower TargetEqual Weight$80.00 ➝ $50.00Low
8/25/2022Alliance Global PartnersInitiated CoverageBuy$150.00Low
8/23/2022Truist FinancialLower TargetHold$100.00 ➝ $60.00Low
6/22/2022HC WainwrightInitiated CoverageBuyLow
4/6/2022Truist FinancialDowngradeBuy ➝ Hold$100.00High
4/1/2022OppenheimerBoost Target$90.00 ➝ $100.00Low
1/27/2022OppenheimerInitiated CoverageOutperform$90.00Medium
11/24/2021Morgan StanleyInitiated CoverageEqual Weight$90.00Medium
10/19/2021Truist FinancialInitiated CoverageBuy$120.00Medium
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/22/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/21/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 2 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Celularity logo
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
Read More

Today's Range

Now: $3.03
Low: $3.03
High: $3.30

50 Day Range

MA: $4.74
Low: $3.03
High: $6.96

52 Week Range

Now: $3.03
Low: $1.59
High: $8.90

Volume

23,621 shs

Average Volume

44,783 shs

Market Capitalization

$58.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Celularity?

The following sell-side analysts have issued reports on Celularity in the last twelve months:
View the latest analyst ratings for CELU.

What is the current price target for Celularity?

0 Wall Street analysts have set twelve-month price targets for Celularity in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Celularity in the next year.
View the latest price targets for CELU.

What is the current consensus analyst rating for Celularity?

Celularity currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CELU.

What other companies compete with Celularity?

Other companies that are similar to Celularity include Immix Biopharma, Rallybio, Landos Biopharma, Marinus Pharmaceuticals and Kronos Bio. Learn More about companies similar to Celularity.

How do I contact Celularity's investor relations team?

Celularity's physical mailing address is 1325 AVENUE OF THE AMERICAS 25TH FLOOR, NEW YORK NY, 10019. The company's listed phone number is 908-768-2170 and its investor relations email address is [email protected]. The official website for Celularity is www.celularity.com. Learn More about contacing Celularity investor relations.